{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:19:17Z","timestamp":1783401557276,"version":"3.54.6"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10067-026-08223-7","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T07:51:20Z","timestamp":1781337080000},"page":"4187-4196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Upfront low-dose biosimilar rituximab as first biologic therapy after triple csDMARD failure in seropositive rheumatoid arthritis: a prospective real-world strategy study"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3766-1809","authenticated-orcid":false,"given":"Ashaq","family":"Parrey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adarsh","family":"Lakshman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajaz","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"key":"8223_CR1","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388:2023\u20132038","journal-title":"Lancet"},{"key":"8223_CR2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RB, Bijlsma JW et al (2020) EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 79:685\u2013699","journal-title":"Ann Rheum Dis"},{"key":"8223_CR3","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/art.41752","volume":"73","author":"JA Singh","year":"2021","unstructured":"Singh JA, Guyatt G, Ogdie A et al (2021) 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 73:1108\u20131123","journal-title":"Arthritis Rheumatol"},{"key":"8223_CR4","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41577-021-00603-1","volume":"21","author":"IB McInnes","year":"2021","unstructured":"McInnes IB, Gravallese EM (2021) Immune-mediated inflammatory disease therapeutics: past, present and future. Nat Rev Immunol 21:680\u2013686","journal-title":"Nat Rev Immunol"},{"key":"8223_CR5","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/art.21778","volume":"54","author":"P Emery","year":"2006","unstructured":"Emery P, Fleischmann R, Filipowicz-Sosnowska A et al (2006) Rituximab plus methotrexate for rheumatoid arthritis: the DANCER trial. Arthritis Rheum 54:1390\u20131400","journal-title":"Arthritis Rheum"},{"key":"8223_CR6","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JC Edwards","year":"2004","unstructured":"Edwards JC, Szczepanski L, Szechinski J et al (2004) Efficacy of rituximab in rheumatoid arthritis. N Engl J Med 350:2572\u20132581","journal-title":"N Engl J Med"},{"key":"8223_CR7","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha D, Smolen JS (2018) Diagnosis and management of rheumatoid arthritis: a review. JAMA 320:1360\u20131372","journal-title":"JAMA"},{"key":"8223_CR8","first-page":"340","volume":"80","author":"L Kearsley-Fleet","year":"2021","unstructured":"Kearsley-Fleet L, Davies R, De Cock D et al (2021) Long-term effectiveness and safety of rituximab: UK BSRBR-RA. Ann Rheum Dis 80:340\u2013348","journal-title":"Ann Rheum Dis"},{"key":"8223_CR9","first-page":"1502","volume":"61","author":"O Barrett","year":"2022","unstructured":"Barrett O, Lunt M, Davies R et al (2022) Real-world effectiveness of rituximab in rheumatoid arthritis: BSRBR-RA analysis. Rheumatology (Oxford) 61:1502\u20131511","journal-title":"Rheumatology (Oxford)"},{"key":"8223_CR10","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000993","volume":"5","author":"K Chatzidionysiou","year":"2019","unstructured":"Chatzidionysiou K, Nikiphorou E, Gossec L et al (2019) Effectiveness of rituximab in routine clinical practice: CERERRA update. RMD Open 5:e001015","journal-title":"RMD Open"},{"key":"8223_CR11","first-page":"2975","volume":"40","author":"M Benucci","year":"2021","unstructured":"Benucci M, Damiani A, Infantino M et al (2021) Updated real-world evidence on rituximab in rheumatoid arthritis. Clin Rheumatol 40:2975\u20132983","journal-title":"Clin Rheumatol"},{"key":"8223_CR12","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1016\/S2665-9913(21)00011-4","volume":"3","author":"R Yusuf","year":"2021","unstructured":"Yusuf R, Salik I, Ahmed S et al (2021) Access to biologic therapies in low-resource settings: global challenges and opportunities. Lancet Rheumatol 3:e236\u2013e245","journal-title":"Lancet Rheumatol"},{"key":"8223_CR13","first-page":"648","volume":"78","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, Aletaha D, Carmona L et al (2019) Monitoring of rheumatoid arthritis in clinical practice: updated EULAR guidance. Ann Rheum Dis 78:648\u2013656","journal-title":"Ann Rheum Dis"},{"key":"8223_CR14","first-page":"1","volume":"30","author":"S Mori","year":"2020","unstructured":"Mori S, Yoshitama T, Ueki Y (2020) Low-dose rituximab in rheumatoid arthritis: updated clinical evidence. Mod Rheumatol 30:1\u20139","journal-title":"Mod Rheumatol"},{"key":"8223_CR15","first-page":"2102","volume":"60","author":"RF van Vollenhoven","year":"2021","unstructured":"van Vollenhoven RF, Takeuchi T, Kapetanovic MC et al (2021) Updated real-world insights on rituximab in rheumatoid arthritis. Rheumatology (Oxford) 60:2102\u20132112","journal-title":"Rheumatology (Oxford)"},{"key":"8223_CR16","first-page":"2975","volume":"40","author":"M Benucci","year":"2021","unstructured":"Benucci M, Damiani A, Infantino M et al (2021) Rituximab biosimilars in rheumatoid arthritis: real-world effectiveness. Clin Rheumatol 40:2975\u20132983","journal-title":"Clin Rheumatol"},{"key":"8223_CR17","first-page":"690","volume":"37","author":"H Tahir","year":"2019","unstructured":"Tahir H, Darroch F, Hughes G et al (2019) Low-dose rituximab versus standard dose in rheumatoid arthritis: a real-world comparison. Clin Exp Rheumatol 37:690\u2013697","journal-title":"Clin Exp Rheumatol"},{"key":"8223_CR18","volume":"19","author":"C Magro-Checa","year":"2020","unstructured":"Magro-Checa C, Steup-Beekman GM, Huizinga TW et al (2020) Low-dose rituximab protocols in autoimmune diseases. Autoimmun Rev 19:102517","journal-title":"Autoimmun Rev"},{"key":"8223_CR19","first-page":"1701","volume":"39","author":"HP Tony","year":"2020","unstructured":"Tony HP, Burmester G, Schulze-Koops H et al (2020) Time course of response after rituximab in rheumatoid arthritis. Clin Rheumatol 39:1701\u20131709","journal-title":"Clin Rheumatol"},{"key":"8223_CR20","first-page":"340","volume":"80","author":"L Kearsley-Fleet","year":"2021","unstructured":"Kearsley-Fleet L, Davies R, De Cock D et al (2021) Long-term effectiveness of rituximab in routine care: BSRBR-RA. Ann Rheum Dis 80:340\u2013348","journal-title":"Ann Rheum Dis"},{"key":"8223_CR21","first-page":"1502","volume":"61","author":"O Barrett","year":"2022","unstructured":"Barrett O, Lunt M, Davies R et al (2022) Real-world outcomes of rituximab: UK registry. Rheumatology (Oxford) 61:1502\u20131511","journal-title":"Rheumatology (Oxford)"},{"key":"8223_CR22","volume":"5","author":"K Chatzidionysiou","year":"2019","unstructured":"Chatzidionysiou K, Nikiphorou E, Gossec L et al (2019) CERERRA collaboration update RMD Open 5:e001015","journal-title":"CERERRA collaboration update RMD Open"},{"key":"8223_CR23","first-page":"1","volume":"21","author":"JD Isaacs","year":"2019","unstructured":"Isaacs JD, Cohen SB, Emery P et al (2019) Predictors of rituximab response in rheumatoid arthritis. Arthritis Res Ther 21:1\u20139","journal-title":"Arthritis Res Ther"},{"key":"8223_CR24","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1136\/annrheumdis-2020-eular.4754","volume":"79","author":"J Sellam","year":"2020","unstructured":"Sellam J, Hendel-Chavez H, Rouanet S et al (2020) Serological predictors of rituximab response. Ann Rheum Dis 79:697\u2013705","journal-title":"Ann Rheum Dis"},{"key":"8223_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2022.154273","volume":"241","author":"V Ricci","year":"2023","unstructured":"Ricci V, Ricci C, Tamborrini G, Chang KV, Mezian K, Zunica F, Na\u0148ka O, Kara M, \u00d6z\u00e7akar L (2023) From histology to sonography in synovitis: EURO-MUSCULUS\/USPRM approach. Pathol Res Pract 241:154273","journal-title":"Pathol Res Pract"},{"key":"8223_CR26","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1007\/s10067-024-07119-8","volume":"43","author":"Y Ou","year":"2024","unstructured":"Ou Y, Wu J, Zhu Y et al (2024) Application of superb microvascular imaging technology in clinical disease activity of rheumatoid arthritis. Clin Rheumatol 43:3293\u20133300","journal-title":"Clin Rheumatol"},{"issue":"7","key":"8223_CR27","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1093\/rheumatology\/keaa785","volume":"60","author":"T Santiago","year":"2021","unstructured":"Santiago T, Voshaar M, De Wit M, Carvalho PD, Buttgereit F, Cutolo M et al (2021) Patients\u2019 and rheumatologists\u2019 perspectives on the efficacy and safety of low-dose glucocorticoids in rheumatoid arthritis-an international survey within the GLORIA study. Rheumatology (Oxford) 60(7):3334\u20133342","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 4 78","key":"8223_CR28","first-page":"S9","volume":"31","author":"R Caporali","year":"2013","unstructured":"Caporali R, Scir\u00e8 CA, Todoerti M, Montecucco C (2013) The role of low-dose glucocorticoids for rheumatoid arthritis in the biologic era. Clin Exp Rheumatol 31(Suppl 4 78):S9-13","journal-title":"Clin Exp Rheumatol"},{"key":"8223_CR29","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1016\/S2665-9913(21)00011-4","volume":"3","author":"R Yusuf","year":"2021","unstructured":"Yusuf R, Salik I, Ahmed S et al (2021) Biologic access barriers in LMICs. Lancet Rheumatol 3:e236\u2013e245","journal-title":"Lancet Rheumatol"},{"key":"8223_CR30","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/1756-185X.13793","volume":"23","author":"R Aggarwal","year":"2020","unstructured":"Aggarwal R, Misra R, Fareed M et al (2020) Biologic availability in Asia. Int J Rheum Dis 23:546\u2013552","journal-title":"Int J Rheum Dis"},{"key":"8223_CR31","first-page":"171","volume":"39","author":"M Kshirsagar","year":"2020","unstructured":"Kshirsagar M, Ghosh A, Handa R et al (2020) Patient affordability of biologics in India. Clin Rheumatol 39:171\u2013178","journal-title":"Clin Rheumatol"},{"key":"8223_CR32","first-page":"e713","volume":"2","author":"RJ Moots","year":"2020","unstructured":"Moots RJ, Azevedo VF, Galloway JB et al (2020) Global experience with biosimilars. Lancet. Rheumatol 2:e713\u2013e723","journal-title":"Rheumatol"},{"key":"8223_CR33","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1002\/acr.24237","volume":"73","author":"J Kay","year":"2021","unstructured":"Kay J, Schoels M, Dorner T et al (2021) Clinical interchangeability of rituximab biosimilars. Arthritis Care Res 73:1300\u20131309","journal-title":"Arthritis Care Res"},{"key":"8223_CR34","first-page":"418","volume":"25","author":"J Woo","year":"2022","unstructured":"Woo J, Choi S, Kim H et al (2022) Rituximab biosimilars in Asia. Int J Rheum Dis 25:418\u2013425","journal-title":"Int J Rheum Dis"},{"key":"8223_CR35","first-page":"1133","volume":"22","author":"AN Malaviya","year":"2019","unstructured":"Malaviya AN, Kapoor S, Garg S et al (2019) Indian experience with low-dose rituximab. Int J Rheum Dis 22:1133\u20131140","journal-title":"Int J Rheum Dis"},{"key":"8223_CR36","first-page":"2845","volume":"40","author":"W Akram","year":"2021","unstructured":"Akram W, Khan S, Hussain N et al (2021) Low-dose rituximab in Pakistani cohorts. Clin Rheumatol 40:2845\u20132852","journal-title":"Clin Rheumatol"},{"key":"8223_CR37","first-page":"873","volume":"29","author":"G T\u00fcrko\u011flu","year":"2019","unstructured":"T\u00fcrko\u011flu G, Yal\u00e7in M, Sahin A et al (2019) Cost-efficient rituximab strategies. Mod Rheumatol 29:873\u2013879","journal-title":"Mod Rheumatol"},{"key":"8223_CR38","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s40744-019-0166-2","volume":"6","author":"S Kapoor","year":"2019","unstructured":"Kapoor S, Kaushik VV, Jain R, Rao V, Gharia M (2019) Real-life tolerability and effectiveness of adalimumab biosimilar in rheumatoid arthritis: ASPIRE registry data. Rheumatol Ther 6:451\u2013459","journal-title":"Rheumatol Ther"},{"key":"8223_CR39","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1111\/1756-185X.13853","volume":"23","author":"A Chopra","year":"2020","unstructured":"Chopra A, Shobha V, Chandrashekara S et al (2020) Tofacitinib in the treatment of Indian patients with rheumatoid arthritis: a post hoc analysis of efficacy and safety in Phase 3 and long-term extension studies over 7 years. Int J Rheum Dis 23:882\u2013897","journal-title":"Int J Rheum Dis"},{"key":"8223_CR40","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RB, Bijlsma JW et al (2020) EULAR management recommendations. Ann Rheum Dis 79:685\u2013699","journal-title":"Ann Rheum Dis"},{"key":"8223_CR41","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1136\/annrheumdis-2019-eular.3118","volume":"78","author":"P Emery","year":"2019","unstructured":"Emery P, D\u00f6rner T, Smolen JS et al (2019) Early biologics in seropositive rheumatoid arthritis. Ann Rheum Dis 78:434\u2013445","journal-title":"Ann Rheum Dis"},{"key":"8223_CR42","first-page":"1947","volume":"39","author":"SS Uppal","year":"2020","unstructured":"Uppal SS, Patel S, Nadkarni N et al (2020) Early rituximab in severe rheumatoid arthritis. Clin Rheumatol 39:1947\u20131955","journal-title":"Clin Rheumatol"},{"key":"8223_CR43","first-page":"607","volume":"17","author":"E Choy","year":"2021","unstructured":"Choy E (2021) Aggressive rheumatoid arthritis phenotypes. Nat Rev Rheumatol 17:607\u2013618","journal-title":"Nat Rev Rheumatol"},{"key":"8223_CR44","first-page":"648","volume":"78","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, Aletaha D, Carmona L et al (2019) Monitoring rheumatoid arthritis in practice. Ann Rheum Dis 78:648\u2013656","journal-title":"Ann Rheum Dis"},{"key":"8223_CR45","first-page":"110","volume":"38","author":"JK Park","year":"2020","unstructured":"Park JK, Lee YJ, Shin K et al (2020) Rituximab response trajectories. Clin Exp Rheumatol 38:110\u2013118","journal-title":"Clin Exp Rheumatol"},{"key":"8223_CR46","first-page":"509","volume":"16","author":"I Sanz","year":"2020","unstructured":"Sanz I, Lee FE, Anolik JH (2020) Advances in B-cell biology. Nat Rev Rheumatol 16:509\u2013528","journal-title":"Nat Rev Rheumatol"},{"key":"8223_CR47","first-page":"163","volume":"39","author":"D S\u00e1nchez-Cano","year":"2019","unstructured":"S\u00e1nchez-Cano D, Rodr\u00edguez-Garc\u00eda V, P\u00e9rez-Guijo V et al (2019) Rituximab outcomes in Southern Europe. Rheumatol Int 39:163\u2013171","journal-title":"Rheumatol Int"},{"key":"8223_CR48","first-page":"1","volume":"21","author":"P Roll","year":"2019","unstructured":"Roll P, Palanichamy A, Kneitz C et al (2019) B-cell repopulation after rituximab. Arthritis Res Ther 21:1\u201310","journal-title":"Arthritis Res Ther"},{"key":"8223_CR49","first-page":"1551","volume":"40","author":"A Valenzuela","year":"2021","unstructured":"Valenzuela A, Mena-V\u00e1zquez N, Manrique-Arija S et al (2021) Durability of response to low-dose rituximab. Clin Rheumatol 40:1551\u20131560","journal-title":"Clin Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08223-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08223-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08223-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:03:27Z","timestamp":1783400607000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08223-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["8223"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08223-7","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,13]]},"assertion":[{"value":"27 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Ethical approval was obtained from the Institutional Ethics Committee, Government Medical College Srinagar (Ref. No. IRB-GMC\/GEN-MED\/212).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}